Looking to clarify and simplify your CCI approval?

Container closure integrity (CCI) is a fundamental requirement of every sterile drug product.  The United States Pharmacopeial Convention (USP) released Chapter <1207> Packaging Integrity Evaluation – Sterile Products, in 2016.  This chapter provides several new concepts which reinforce a risk-based approach that is based on the fundamentals of sound science.

CCI is a very complex issue, however, the right approach can simplify it. This webinar will provide six key areas to consider in view of Chapter <1207> that enable a holistic approach to optimize sterile product package CCI.

Featured Speakers

Fran L. DeGrazio

Vice President, Global Scientific Affairs &Technical Services
West Pharmaceutical Services

Christopher Barnes

Technology Manager, Container Closure Integrity
West Analytical Labs

Register now for this webinar